Ephraim Heller

Ephraim Heller is the Founding CEO of SynAgile. Ephraim was Founding CEO of AngioScore Inc., a balloon angioplasty company acquired by Spectranetics for over $230 million in 2014. Before that, he was Founding CEO and later VP of Marketing and VP of Business Development at TheraSense Inc., a maker of blood glucose monitoring systems for people with diabetes. TheraSense went public in 2001, sales grew to $270 million in 2003, and the company was acquired by Abbott for $1.2 billion in 2004. Ephraim holds over 100 issued US patents. He received a BA in Physics from Harvard and an MBA from Yale.